Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

243.80 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

August 04, 2026

Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)

From American News Group

Via GlobeNewswire

AbbVie (ABBV) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Revenue beat guidance as immunology and neuroscience portfolios drive growth.

Via The Motley Fool

Topics Earnings Economy

The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure ↗

August 03, 2026

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results ↗

July 31, 2026

Via Chartmill

Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays ↗

July 30, 2026

Via Chartmill

Topics Cannabis

AbbVie Quietly Solved Its Biggest Problem—Now What? ↗

August 02, 2026

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

Via MarketBeat

Topics Intellectual Property

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

August 01, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 ...

Via StockStory

Why AbbVie Stock Slumped Today ↗

July 31, 2026

The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.

Via The Motley Fool

Topics Earnings

Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today ↗

July 31, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of...

Via Benzinga

AbbVie Q2 Earnings Call Highlights ↗

July 31, 2026

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue...

Via MarketBeat

Topics ETFs Earnings

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat ↗

July 31, 2026

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Via Benzinga

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

July 31, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-G...

Via StockStory

Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗

July 31, 2026

Via Chartmill

What To Expect From AbbVie’s (ABBV) Q2 Earnings

July 29, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for. AbbVie beat analysts’...

Via StockStory

Topics Artificial Intelligence

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

But is that performance sustainable?

Via The Motley Fool

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Should You Buy AbbVie Stock Hand Over Fist Before July 31? ↗

July 27, 2026

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

Via The Motley Fool

Topics Earnings Intellectual Property

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? ↗

July 26, 2026

Both have very promising futures.

Via The Motley Fool

Why Wall Street Can't Get Enough of This Dividend King ↗

July 25, 2026

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Via The Motley Fool

Topics Intellectual Property

2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗

July 24, 2026

There are plenty of reasons to love these companies.

Via The Motley Fool

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

July 23, 2026

From Genmab A/S and AbbVie

Via Business Wire

I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation ↗

July 23, 2026

When quality goes on sale, it's time to back up the truck.

Via The Motley Fool

Topics Intellectual Property

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗

July 21, 2026

It looks like a great buy-and-hold option.

Via The Motley Fool

Topics Intellectual Property

PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗

July 20, 2026

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

Via The Motley Fool

Topics ETFs

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗

July 19, 2026

There's no need to panic.

Via The Motley Fool

My 2 Favorite Dividend Kings to Buy Right Now ↗

July 19, 2026

They can help stabilize your portfolio in these otherwise volatile times.

Via The Motley Fool

Topics Intellectual Property

Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today ↗

July 17, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basis producing an average annual return of 14.83%. Currently, AbbVie has a market capitalization of...

Via Benzinga

3 Rock-Solid Dividend Stocks to Buy and Hold for Decades ↗

July 14, 2026

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.

Via The Motley Fool

Topics Intellectual Property

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗

July 14, 2026

Drug pricing matters, but pipelines matter even more.

Via The Motley Fool

Topics Government Intellectual Property

3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors ↗

July 13, 2026

You need to look beyond the tech sector to find great dividend stocks for the long term.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AbbVie (NY:ABBV)

All News about AbbVie

Starting at /week.